Afficher la couverture 'Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension | Masson, Bastien' en grand format
/5

0 avis

Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension

Archive ouverte

Masson, Bastien | Le Ribeuz, Hélène | Sabourin, Jessica | Laubry, Loann | Woodhouse, Emily | Foster, Richard | Ruchon, Yann | Dutheil, Mary | Boët, Angèle | Ghigna, Maria-Rosa | de Montpreville, Vincent Thomas | Mercier, Olaf | Beech, David | Benitah, Jean-Pierre | Bailey, Marc, A | Humbert, Marc | Montani, David | Capuano, Véronique | Antigny, Fabrice

Edité par CCSD ; American Heart Association -

International audience. Rationale: Pulmonary arterial hypertension (PAH) is characterized by progressive distal pulmonary artery (PA) obstruction, leading to right ventricular hypertrophy and failure. Exacerbated intracellular calcium (Ca2+) signaling contributes to abnormalities in PA smooth muscle cells (PASMCs), including aberrant proliferation, apoptosis resistance, exacerbated migration, and arterial contractility. Store-operated Ca2+ entry (SOCE) is involved in Ca2+ homeostasis in PASMCs, but its properties in PAH are unclear.Methods: Using a combination of Ca2+ imaging, molecular biology, in-vitro, ex-vivo, and in-vivo approaches, we investigated the roles of the Orai1 SOC channel in PA remodeling in PAH and determined the consequences of pharmacological Orai1 inhibition in vivo using experimental models of pulmonary hypertension (PH). Results: SOCE and Orai1 mRNA and protein were increased in human PASMCs (hPASMCs) from patients with PAH (PAH-hPASMCs). We found that MEK1/2, nuclear factor of activated T cells (NFAT), and nuclear factor-kappa B (NFƘB) contribute to the upregulation of Orai1 expression in PAH-hPASMCs. Using siRNA and Orai1 inhibitors, we found that Orai1 inhibition reduced SOCE, mitochondrial Ca2+ uptake, aberrant proliferation, apoptosis resistance, migration, and excessive calcineurin activity in PAH-hPASMCs. Orai1 inhibitors reduced agonist-evoked constriction in human PAs. In experimental rat models of PH evoked by chronic-hypoxia, monocrotaline, or Sugen/hypoxia, administration of Orai1 inhibitors (BTP2, JPIII, or 5J4) protected against PH. Conclusions: In human PAH and experimental PH, Orai1 expression and activity are increased. Orai1 inhibition normalizes the PAH-hPASMCs phenotype and attenuates PH in rat models. These results suggest that Orai1 should be considered as a relevant therapeutic target for PAH.

Suggestions

Du même auteur

Contribution of TRPC channels in human and experimental pulmonary arterial hypertension. Contribution of TRPC channels in human and experimental pulmonary arterial hypertension: Short title : TRPC channels in PAH

Archive ouverte | Masson, Bastien | CCSD

International audience. TRPC3 is increased in human and experimental pulmonary arterial hypertension (PAH). In PAH pulmonary arterial smooth muscle cells, TRPC3 participates in the aberrant store-operated Ca 2+ entr...

Involvement of SUR2/Kir6.1 channel in the physiopathology of pulmonary arterial hypertension

Archive ouverte | Le Ribeuz, Hélène | CCSD

International audience. Aims: We hypothesized that the ATP-sensitive K+ channels (KATP) regulatory subunit (ABCC9) contributes to PAH pathogenesis. ABCC9 gene encodes for two regulatory subunits of KATP channels: th...

SUR1 as a new therapeutic target for pulmonary arterial hypertension

Archive ouverte | Le Ribeuz, Hélène | CCSD

International audience. Mutations in ABCC8 have been identified in pulmonary arterial hypertension (PAH). ABCC8 encodes SUR1, a regulatory subunit of the ATP-sensitive potassium channel Kir6.2. However, the pathophy...

Chargement des enrichissements...